Bryn Pharma LLC

Bryn Pharma LLC develops innovative medical solutions, specializing in a needle-free epinephrine nasal spray designed to provide a user-friendly and accessible emergency treatment for anaphylaxis. Bryn Pharma LLC, founded in 2017, is headquartered in Raleigh, US, and focuses on creating a pioneering epinephrine delivery system. The company has not undergone any significant pivots or changes in its business strategy. The founders, Michelle Lobel and Steven Hartman, have personal experiences with anaphylaxis that drive their mission.

The company raised USD 11 mn in venture funding on August 4, 2020, marking its total capital raised at USD 11 mn. Bryn Pharma is focused on developing a pioneering epinephrine nasal spray aimed at addressing the urgent needs of individuals at risk for anaphylaxis. The core product is a needle-free, portable, and user-friendly epinephrine delivery system that eliminates the fear and complexity associated with traditional needle-based devices. This innovation is designed for easy administration without the need for medical training, thereby increasing accessibility for patients and caregivers.

The company’s commitment to enhancing patient experience stems from the personal experiences of its founders, who are directly affected by anaphylaxis. Bryn Pharma’s products are anticipated to serve a wide customer base, including individuals with allergies, parents of children at risk, and healthcare providers. While the company is based in the United States, its products aim to reach various international markets where the need for emergency anaphylaxis treatment is prevalent. Bryn Pharma's revenue model is centered around direct sales of its epinephrine nasal spray to consumers and healthcare institutions, facilitating accessibility for patients in need of emergency treatment.

The company also plans to explore partnerships with pharmacies, hospitals, and healthcare providers to expand its reach and ensure availability of its innovative product. Transactions are structured through business-to-consumer (B2C) sales and business-to-business (B2B) agreements with medical facilities. The primary product, the epinephrine nasal spray, is positioned as an affordable alternative to existing epinephrine auto-injectors, reflecting a strategic pricing approach that caters to a broad range of potential users. Bryn Pharma plans to utilize the USD 11 mn raised in August 2020 to support the development of new products, including advancements in its epinephrine nasal spray.

The company is also targeting expansion into international markets where demand for emergency anaphylaxis treatments is high, although specific regions have not been disclosed. The funding will be critical for executing these initiatives and supporting the anticipated product launches.